March 18, 2022 06:44 AM EDT
R&D
Pharma

Hot on Roche’s heels, Mer­ck spells out mixed Keytru­da da­ta in ad­ju­vant NSCLC

Amber Tong

Is Mer­ck ready to crack open a ma­jor new mar­ket for its PD-1 star?

The phar­ma gi­ant said so as it re­leased full da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times